Vertex Pharmaceuticals said its drug for a rare kidney condition succeeded in a Phase 3 trial. The drug, povetacicept, is a central piece of the company's plan to expand into kidney disease. Vertex ...

DEARBORN HEIGHTS, Mich. – Vista Maria announced it will permanently lay off over 150 employees as its residential program discontinues. Kathleen Regan, the Chief Executive Officer of Vista Maria, sent ...

Treating pain has long been a challenge. Over-the-counter treatments often don’t do enough, while opioids block pain signals but can be extremely addictive. Vertex broke those barriers with Journavx, ...

The acquisition of Adams marks Vertex’s seventh acquisition under Wind Point ownership Jeff Christmann serves as CEO of Adams The Vertex Companies, a portfolio company of Wind Point Partners, has ...

Vertex Pharmaceuticals Inc. (NASDAQ:VRTX) stock is falling on Tuesday after the company’s pain data overshadowed strong second-quarter earnings. See real-time price for VRTX stock here. On Monday, the ...

Bill McColl has 25+ years of experience as a senior producer and writer for TV, radio, and digital media leading teams of anchors, reporters, and editors in creating news broadcasts, covering some of ...

A Vertex Pharmaceuticals drug viewed as a successor to a non-opioid pill that won a landmark FDA approval earlier this year has failed a mid-stage clinical trial, dealing a setback to the company’s ...

OF THE AREA MEDIAN INCOME. A GLOBAL BIOTECH COMPANY IS FOSTERING TALENT AMONG BOSTON PUBLIC SCHOOL KIDS. OUR ERIKA TARANTAL REPORTS ON THE PAID INTERNSHIP PROGRAM, GIVING STUDENTS THE OPPORTUNITY OF A ...

Vertex's fourth Seaport building will join another across Northern Avenue. The company also has two larger buildings on Fan Pier. Gary Higgins / Boston Business ...

KING OF PRUSSIA, June 10, 2025 (GLOBE NEWSWIRE) -- Vertex Inc. (VERX) (NASDAQ:VERX) (“Vertex” or the “Company”), a leading global provider of indirect tax solutions, today announced it has been ...

Vertex Pharmaceuticals is pressing pause on a phase 1/2 cystic fibrosis (CF) trial over a tolerability issue while reporting a separate impairment charge of $379 million tied to an earlier ...